Cite
HARVARD Citation
Aliyev, E. et al. (2019). Cost‐Effectiveness Comparison of Ustekinumab, Infliximab, or Adalimumab for the Treatment of Moderate‐Severe Crohn's Disease in Biologic‐Naïve Patients. Pharmacotherapy. 39 (2), pp. 118-128. [Online].